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Abstract
Objectives The aim of this study was to compare the
efficacy and safety of the prodrug psychostimulant lis-
dexamfetamine dimesylate (LDX) and the non-stimulant
noradrenergic compound atomoxetine (ATX) in children
and adolescents with attention-deficit/hyperactivity disor-
der (ADHD) who had previously responded inadequately
to methylphenidate (MPH).
Methods This 9-week, head-to-head, randomized, double-
blind, active-controlled study (SPD489-317; ClinicalTri-
als.gov NCT01106430) enrolled patients (aged 6–17 years)
with at least moderately symptomatic ADHD and an inade-
quate response to previous MPH therapy. Patients were
randomized (1:1) to an optimized daily dose of LDX (30, 50
or 70 mg) or ATX (patients \70 kg, 0.5–1.2 mg/kg with
total daily dose not to exceed 1.4 mg/kg; patients C70 kg, 40,
80 or 100 mg). The primary efficacy outcome was time
(days) to first clinical response. Clinical response was defined
as a Clinical Global Impressions-Improvement (CGI-I) score
of 1 (very much improved) or 2 (much improved). Secondary
efficacy outcomes included the proportion of responders at
each study visit and the change from baseline in ADHD
Rating Scale (ADHD-RS-IV) and CGI-Severity scores.
Tolerability and safety were assessed by monitoring treat-
ment-emergent adverse events (TEAEs), height and weight,
vital signs and electrocardiogram parameters. Endpoint was
defined as the last post-baseline, on-treatment visit with a
valid assessment.
Results Of 267 patients randomized (LDX, n = 133;
ATX, n = 134), 200 (74.9 %) completed the study. The
median time to first clinical response [95 % confidence
interval (CI)] was significantly shorter for patients receiv-
ing LDX [12.0 days (8.0–16.0)] than for those receiving
ATX [21.0 days (15.0–23.0)] (p = 0.001). By week 9,
81.7 % (95 % CI 75.0–88.5) of patients receiving LDX had
responded to treatment compared with 63.6 % (95 % CI
55.4–71.8) of those receiving ATX (p = 0.001). Also by
week 9, the difference between LDX and ATX in least-
squares mean change from baseline (95 % CI) was sig-
nificant in favour of LDX for the ADHD-RS-IV total score
[-6.5 (-9.3 to -3.6); p \ 0.001; effect size 0.56],
inattentiveness subscale score [-3.4 (-4.9 to -1.8);
p \ 0.001; effect size 0.53] and the hyperactivity/impul-
sivity subscale score [-3.2 (-4.6 to -1.7); p \ 0.001;
effect size 0.53]. TEAEs were reported by 71.9 and 70.9 %
of patients receiving LDX and ATX, respectively. At
ClinicalTrials.gov NCT01106430.
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endpoint, both treatments were associated with mean
(standard deviation) increases in systolic blood pressure
[LDX, ?0.7 mmHg (9.08); ATX, ?0.6 mmHg (7.96)],
diastolic blood pressure [LDX, ?0.1 mmHg (8.33); ATX,
?1.3 mmHg (8.24)] and pulse rate [LDX, ?3.6 bpm
(10.49); ATX, ?3.7 bpm (10.75)], and decreases in weight
[LDX, -1.30 kg (1.806); ATX, -0.15 kg (1.434)].
Conclusions LDX was associated with a faster and more
robust treatment response than ATX in children and ado-
lescents with at least moderately symptomatic ADHD who
had previously responded inadequately to MPH. Both
treatments displayed safety profiles consistent with findings
from previous clinical trials.
1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is esti-
mated to affect 5 % of children worldwide, making it one
of the most common neurodevelopmental disorders in
children and adolescents [1]. There are considerable dif-
ferences in the worldwide availability of medications for
ADHD. In North America, methylphenidate (MPH)- and
amfetamine-based psychostimulants are considered first-
line ADHD therapies, and a variety of short- and long-
acting formulations are available [2, 3]. In Europe, short-
and long-acting MPH formulations are widely available,
and MPH is generally considered to be the first-line med-
ication for ADHD [4]. Until recently, only short-acting
formulations of amfetamine have been approved in Europe,
and only in some countries [4]. Of non-stimulant ADHD
medications, the noradrenaline reuptake inhibitor ato-
moxetine (ATX) is approved in North America and several
European countries [5], and the a2-adrenergic agonists
clonidine and guanfacine are licensed in the USA but not
Europe [6, 7].
Lisdexamfetamine dimesylate (LDX) is a long-acting
prodrug treatment for patients with ADHD [8]. Multiple
randomized, double-blind, placebo-controlled trials have
shown LDX to be an effective treatment for children,
adolescents and adults with ADHD, with a tolerability and
safety profile consistent with the known effects of psy-
chostimulant therapy [9–15]. LDX is approved as a first-
line treatment for ADHD in the USA, Canada and Brazil.
In early 2013, LDX became the first long-acting, amfeta-
mine-based medication to be approved in Europe, where it
is licensed in several countries for the treatment of children
and adolescents with ADHD who have had a clinically
inadequate response to MPH. Here, we present results from
a head-to-head, 9-week, double-blind, randomized, active-
controlled, phase IIIb study (SPD489-317; ClinicalTri-
als.gov NCT01106430). This study was designed to
provide a direct comparison of the efficacy and safety of
LDX and ATX in children and adolescents with ADHD
who had experienced an inadequate response to previous
MPH therapy. These results will aid clinicians when
developing individualized treatment plans for the man-
agement of patients with ADHD.
2 Methods
This double-blind, randomized, active-controlled, parallel-
group study was approved by an independent ethics com-
mittee/institutional review board and regulatory agency in
each centre (as appropriate). The study was conducted in
accordance with current applicable regulations, the Inter-
national Conference on Harmonization of Good Clinical
Practice [16] and local ethical and legal requirements.
Before enrolment in the study, written, informed consent
was obtained from the necessary parent(s) or legal guard-
ian(s) for each patient, in accordance with local require-
ments, and assent was also obtained from each patient,
when applicable.
2.1 Study Population
This study enrolled male and female patients (aged
6–17 years) who satisfied Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) [17] criteria for a primary diagnosis of
ADHD of at least moderate severity as shown by a baseline
ADHD Rating Scale IV (ADHD-RS-IV) total score of 28
or higher. Inclusion and exclusion criteria related to a
patient’s previous exposure and/or response to ADHD
medications are outlined in Table 1. Other inclusion cri-
teria included age-appropriate intellectual functioning;
ability to swallow a capsule; and blood pressure measure-
ments within the 95th percentile for age, sex and height.
Female patients of childbearing potential were required to
have a negative urine pregnancy test at baseline and to
comply with the contraceptive requirements of the proto-
col. Other key exclusion criteria included comorbid psy-
chiatric diagnosis with significant symptoms (based on
Kiddie-Schedule for Affective Disorders and Schizophre-
nia for School Age Children—Present and Lifetime diag-
nostic interview); conduct disorder (excluding oppositional
defiant disorder); suicide risk, with a previous suicide
attempt or active suicidal ideation; pregnancy or lactation;
weight below 22.7 kg; body mass index (BMI, kg/m2)
greater than the 97th percentile for age and sex; positive
urine drug test (with the exception of a patient’s
current ADHD medication); clinically significant
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electrocardiogram (ECG) results or laboratory abnormali-
ties; known CYP2D6 poor-metabolizer genotype; sus-
pected substance abuse or dependence disorder (excluding
nicotine) within the previous 6 months; history of seizures;
tics or Tourette’s disorder; pre-existing liver disease or
laboratory evidence of liver disease; known cardiac struc-
tural abnormality; or any other condition that might increase
vulnerability to the sympathomimetic effects of a psycho-
stimulant drug.
2.2 Study Design
Patients were required to discontinue any psychoactive
medication for a 7-day washout period prior to baseline
(visit 0). At baseline, patients were randomized (1:1) to
receive a once-daily, morning dose (at 07:00 ± 2 h) of
LDX or ATX for a 9-week, double-blind evaluation period
(Fig. 1) with weekly, on-site efficacy, tolerability and
safety assessments. Dosing began on the morning after the
baseline visit and continued for 9 weeks, starting with a
4-week, stepwise, dose-optimization stage. Randomization
of patients was stratified by country, and an automated
interactive response system was used to generate the ran-
dom (concealed) allocation sequence and assign partici-
pants to study treatments; patients, caregivers and
investigators were blinded to the treatment allocation. All
study drugs were over-encapsulated so they appeared
identical.
The dose-optimization phase involved adjustment of the
dose until an ‘acceptable’ response was achieved [defined
as a reduction of at least 30 % from baseline in the ADHD-
RS-IV total score and a Clinical Global Impressions-
Improvement (CGI-I) score of 1 or 2 with tolerable side
effects]. Only one dose reduction was permitted during the
optimization phase and, following dose reduction, further
increases were not allowed. Dose adjustments were not
permitted beyond visit 3, and patients who were unable to
tolerate the study drug were withdrawn from the study.
LDX was provided in a single capsule of 30, 50 or
70 mg, with patients initially receiving a 30-mg dose. ATX
was available in 10-, 18-, 25-, 40- and 60-mg capsules. All
patients in the ATX group who weighed less than 70 kg
were started on a daily dose of approximately 0.5 mg/kg
body weight, the final target daily dose being 1.2 mg/kg,
with a maximum permitted daily dose of 1.4 mg/kg.
Patients who weighed 70 kg or more initially received
40 mg and, if required, were titrated to 80 mg and then to
100 mg daily. Some patients treated with ATX would need
two capsules to achieve the required dose (e.g. 80 and
100 mg were achieved using two capsules). Therefore, all
patients weighing more than 64.5 kg who were titrated to a
higher dose were instructed to take two capsules (the sec-
ond capsule could be either active drug or placebo, as
appropriate) to maintain the double-blind study design.
2.3 Efficacy
The primary efficacy measure was the time to first clinical
response (days) after the initiation of treatment, as assessed
by CGI-I scores [18]. The CGI scale provides a global
assessment of a patient’s severity of illness; CGI-I scores,
which were reported at each post-baseline visit, rate the
change in a patient’s condition from baseline on a scale of
1 (very much improved) to 7 (very much worse) [18].
Clinical ‘response’ was defined as a CGI-I score of 1 or 2
(very much improved or much improved). The number of
days to first clinical response was calculated as the date of
response minus the date of first dose, plus 1 day.
Secondary efficacy outcomes included the proportion of
CGI-I responders at each study visit, the proportion of
patients who had a decrease of at least one CGI-Severity
(CGI-S) category from baseline (assessed at visit 4 and at
visit 9), and the change from baseline in ADHD-RS-IV
total and subscale scores at each study visit. CGI-S scores,
which rate the severity of a patient’s condition on a scale of
1 (normal, not at all ill) to 7 (among the most extremely
ill), were assessed at baseline, visit 4 and visit 9 [18]. The
ADHD-RS-IV scale [19], designed to reflect current
ADHD symptoms, assesses 18 items on a scale of 0 (no
symptoms) to 3 (severe symptoms), with a total score
ranging from 0 to 54. CGI and ADHD-RS-IV assessments
Table 1 Patient inclusion and exclusion criteria relating to previous
exposure to ADHD medication
Inclusion criteria
1. An inadequate response to previous MPH treatment. This
included, but was not limited to, one or more of the following:
• The presence of some residual ADHD symptoms
• Inadequate duration of action
• Variable symptom control
• If, based on the investigator’s judgement, the patient may
benefit clinically from an alternative to MPH
Exclusion criteria
1. Intolerable adverse events from previous MPH treatment
2. Previous exposure to amfetamine or ATX
3. Previous treatment with more than one MPH medication
• This did not include patients who had received immediate
release MPH for dose titration on a short-term basis (B4 weeks)
provided that they experienced an adequate response
4. Failure to respond to more than one previous course of MPH
medication
• Failure to respond was defined as a worsening, no change or
minimal improvement of symptoms
5. Good control of ADHD symptoms with acceptable tolerability
on current ADHD medication
ADHD attention-deficit/hyperactivity disorder, ATX atomoxetine,
MPH methylphenidate
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were performed by a medical practitioner or psychologist
experienced in the evaluation of children and adolescents
with ADHD.
2.4 Tolerability and Safety
Tolerability and safety assessments included the monitor-
ing of treatment-emergent adverse events (TEAEs), labo-
ratory evaluations, physical examination (including
weight), and monitoring of vital signs and ECG parame-
ters. TEAEs were defined as adverse events that first
occurred or worsened during the time between the first
dose of study drug and the third day following cessation of
treatment (inclusive). All TEAEs were coded using Medi-
cal Dictionary for Regulatory Activities (MedDRA) (ver-
sion 14.1) [20]. A serious TEAE was any untoward medical
occurrence that resulted in death; was life-threatening;
required inpatient hospitalization or prolonged existing
hospitalization; resulted in persistent or significant dis-
ability/incapacity; was a congenital abnormality/birth
defect; or was an Important Medical Event. Important
Medical Events may have been considered as serious TE-
AEs when, based upon medical judgement, they may have
jeopardized the patient and may have required medical or
surgical intervention to prevent one of the outcomes listed
above. The sponsor required any new onset of seizures,
syncope or loss of consciousness to be reported as a serious
TEAE. Using Centers for Disease Control and Prevention
percentile growth charts [21], BMI was categorized into
five groups based on BMI percentiles: underweight
(\5 %), healthy weight (low; C5 to \25 %), healthy
weight (high; C25 to \85 %), at risk of being overweight
(C85 to\95 %) and overweight (C95 %). ECG parameters
were assessed at screening and visit 4. However, the visit 4
ECG was added as a result of a protocol amendment
requested by the French Central Ethics Committee and
therefore was not obtained for all patients. The Brief
Psychiatric Rating Scale for Children (BPRS-C), the
Columbia-Suicide Severity Rating Scale (C-SSRS) and the
Udvalg for Kliniske Undersøgelser Side Effect Rating
Scale-Clinician (UKU-SERS-Clin) were also used to
monitor patient tolerability and safety plus the suitability of
individuals to remain in the study [22–24].
2.5 Statistical Analyses
Safety/tolerability assessments were performed using the
safety population, defined as all patients who were ran-
domized and received at least one dose of study drug.
Efficacy data were analysed using the full analysis set
(FAS), also defined as all patients who were randomized
and received at least one dose of study drug. One patient
was randomized to ATX but received LDX owing to a drug
dispensing error. Based on the intent-to-treat principle, this
patient was included in the ATX treatment group in the
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safety population. Endpoint was defined as the last on-
treatment, post-baseline visit with a valid assessment.
Time to first clinical response (days) was calculated
using Kaplan–Meier estimates and analysed using a Peto–
Peto–Prentice–Wilcoxon (PPPW) test [25, 26], stratified by
country and evaluated at a significance level of 0.05 (two-
sided). The null hypothesis stated that there was no difference
in the time to first clinical response between patients
receiving LDX and those taking ATX, with the two-sided
alternative of a non-zero difference between the groups.
Allowing for a 20 % discontinuation rate, approximately 262
patients (131 in each treatment group) were required to detect
a difference in time to first clinical response between the
treatment groups with a power of 85 %. Patients who pre-
maturely discontinued from the study without responding,
and patients who completed the study up to visit 9 without
meeting response criteria, were censored at visit 9 in the
primary analysis of time to response, and classified as non-
responders in the analysis of responders.
The proportion of responders (CGI-I score of 1 or 2) at
each study visit and the proportion of patients who had a
decrease of at least one CGI-S category by visit 9
were assessed using the last-observation-carried-forward
(LOCF) approach and analysed using a Cochran–Mantel–
Haenszel (CMH) test stratified by country. At each study
visit, the change from baseline in ADHD-RS-IV scores,
using LOCF, was analysed using an analysis of covariance
(ANCOVA) model including treatment group (effect of
interest), country (blocking factor) and the corresponding
baseline score (covariate). Effect sizes were calculated as
the difference in least-squares (LS) mean score between the
two treatments, divided by the root mean square error
obtained from the ANCOVA model. Effect sizes of 0.2, 0.5
and 0.8 correspond to small, medium and large magnitudes
of effect, respectively [27].
3 Results
3.1 Patient Disposition and Baseline Characteristics
This study, conducted between 28 June 2010 and 19 July
2012, enrolled 267 patients from 51 sites in Canada
(n = 35 patients), the USA (n = 138) and seven European
countries (Belgium, n = 2; Germany, n = 42; Hungary,
n = 20; Italy, n = 1; Poland, n = 1; Spain, n = 22; and
Sweden, n = 6). Of 267 patients randomized (LDX,
n = 133; ATX, n = 134), 200 (74.9 %) completed the
study (LDX, n = 99; ATX, n = 101) (Fig. 2). The safety
population comprised all patients who were randomized
and received at least one dose of study drug (LDX,
n = 128; ATX, n = 134). Based on the intent-to-treat
principle, the FAS comprised 262 patients (LDX, n = 127;
ATX, n = 135). The two most commonly reported reasons
for study discontinuation for patients receiving LDX were
adverse events (8/133 patients; 6.0 %) and withdrawal by
patient (8/133; 6.0 %), and for patients receiving ATX they
Randomized (N = 267)
Safety populationa (n = 262)
Full analysis set (FAS)b (n = 262)
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Discontinued (n = 33)
• Adverse event (10)
• Protocol violation (2)
• Withdrawn by 
 patient (4)
• Lost to follow-up (1)
• Lack of efficacy (13)
• Othere (3)
Fig. 2 Patient disposition. aThe safety population included all
patients who were randomized and received at least one dose of
study drug. bThe FAS included all patients who were randomized and
received at least one dose of study drug. One patient was randomized
to ATX but, owing to a drug dispensing error, received LDX. Based
on the intent-to-treat principle, this patient was included in the ATX
treatment group in the FAS. cStudy completers were patients who
completed visits 0–10 (visit 10 being a clinic visit or telephone call).
dOther reasons for discontinuation among patients administered LDX
were difficulty swallowing capsule (n = 1); early termination
requested by the sponsor because of previous marijuana use
(n = 1); and early termination requested by the sponsor because
patient was unable to meet the study visit schedule (n = 1). eOther
reasons for discontinuation among patients administered ATX were
refusal to take medication (n = 1); patient relocation due to a family
emergency (n = 1); and non-compliance (n = 1). ATX atomoxetine,
FAS full analysis set, LDX lisdexamfetamine dimesylate
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were lack of efficacy (13/134 patients; 9.7 %) and adverse
events (10/134; 7.5 %). Baseline characteristics were
similar for both treatment groups (Table 2).
3.2 Dose Optimization
The mean optimal dose (which was the dose that was dis-
pensed at visit 4) for patients who received LDX during the
dose-maintenance phase was 52.5 mg/day [standard deviation
(SD): 16.10]; 28/128 (21.9 %) received 30 mg/day, 36/128
(28.1 %) received 50 mg/day and 41/128 (32.0 %) received
70 mg/day. The mean optimal dose for patients who received
ATX was 40.2 mg/day (SD: 20.05); 15/134 (11.2 %) and
95/134 (70.9 %) received a daily dose of 0.5 mg/kg and
1.2 mg/kg, respectively (patients weighing\70 kg; n = 127),
and 2/134 (1.5 %), 1/134 (0.7 %) and 4/134 (3.0 %) received
40, 80 and 100 mg/day, respectively (patients weighing
C70 kg; n = 7). An optimal dose was not available for
patients who discontinued the study before reaching visit 4
(LDX, n = 23; ATX, n = 17).
3.3 Efficacy
The mean CGI-S score at baseline was 5.0 in both treat-
ment groups (Table 2), with most patients categorized as
Table 2 Baseline characteristics and demographic data (safety
population)
Characteristic LDX (n = 128) ATX (n = 134)
Demographic data
Age, years
Mean (SD) 10.9 (3.01) 10.4 (2.84)
Median (range) 10.0 (6–17) 10.0 (6–17)
Age distribution, years,
n (%)
6–12 94 (73.4) 100 (74.6)
13–17 34 (26.6) 34 (25.4)
Male, n (%) 94 (73.4) 103 (76.9)
Ethnicity, n (%)
Hispanic or Latino 25 (19.5) 24 (17.9)
Not Hispanic or Latino 103 (80.5) 110 (82.1)
Race, n (%)
White 116 (90.6) 117 (87.3)
Height and weight
Height,a cm
Mean (SD) 145.91 (17.446) 144.12 (15.696)
Median (range) 142.00 (113.3–187.4) 143.25 (114.0–177.8)
Weight,a kg
Mean (SD) 41.95 (16.521) 39.14 (14.436)
Median (range) 37.25 (22.9–88.0) 35.65 (22.7–88.0)
BMI,a kg/m2
Mean (SD) 18.92 (3.551) 18.21 (3.224)
Median (range) 17.78 (13.4–31.3) 17.51 (12.7–28.3)
Baseline disease characteristics
CGI-S score at baseline
Mean (SD) 5.0 (0.80) 5.0 (0.73)
Median (range) 5.0 (3–7) 5.0 (4–7)
ADHD-RS-IV total score at baseline
Mean (SD) 42.6 (6.14)b 41.9 (6.70)b
Median (range) 42.0 (28–54) 42.0 (28–53)
ADHD-RS-IV inattention subscale score at baseline
Mean (SD) 22.6 (3.23) 22.5 (3.12)
Median (range) 23.0 (13–27) 23.0 (11–27)
ADHD-RS-IV hyperactivity/impulsivity subscale score at baseline
Mean (SD) 20.0 (4.68) 19.4 (5.71)
Median (range) 20.0 (6–27) 20.0 (2–27)
ADHD subtype, n (%)
Predominantly
inattentive
22 (17.2) 22 (16.4)
Predominantly
hyperactive-impulsive
2 (1.6) 7 (5.2)
Combined 104 (81.3) 105 (78.4)
Time since ADHD diagnosis, years
Mean (SD) 2.81 (2.746) 2.11 (1.936)
Median (range) 1.94 (0.0–12.9) 1.57 (0.0–8.2)
Concomitant psychiatric diagnosis,c n (%)
Any 27 (21.1) 23 (17.2)
Oppositional defiant
disorder
13 (10.2) 13 (9.7)
Table 2 continued
Characteristic LDX (n = 128) ATX (n = 134)
ADHD medication history
Previously treated with ADHD medication, n (%)
Any ADHD medication 128 (100) 134 (100)
Any methylphenidate
medicationd
127 (99.2) 134 (100)
Reasons for inadequate response to methylphenidate,e n (%)
Lack of efficacy 96 (75.0) 106 (79.1)
Intolerability 8 (6.3) 8 (6.0)
Other 42 (32.8) 53 (39.6)
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV ADHD Rating
Scale IV, ATX atomoxetine, BMI body mass index, CGI-S Clinical Global
Impressions-Severity, LDX lisdexamfetamine dimesylate, SD standard
deviation
a As height was only measured at the screening visit, the values for height,
weight (used to calculate BMI) and BMI are those obtained at screening
b The observed baseline ADHD-RS-IV scores indicate moderate or severe
illness [42]
c Patients with at least one ongoing psychiatric diagnosis, as determined by
the Kiddie-Schedule for Affective Disorders and Schizophrenia for School
Age Children—Present and Lifetime diagnostic interview
d Methylphenidate medication includes methylphenidate, methylphenidate
hydrochloride, dexmethylphenidate and dexmethylphenidate hydrochloride.
Patients may have received more than one type of ADHD medication but
not more than one methylphenidate medication. One patient in the LDX
group had not received any previous methylphenidate
e Patients may have listed more than one reason
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moderately ill or markedly ill (LDX, 97/127; ATX,
104/135). The median time to first clinical response (CGI-I
score of 1 or 2) was significantly shorter for patients
receiving LDX [12.0 days (95 % confidence interval
[CI] 8.0–16.0)] than those receiving ATX [21.0 days
(15.0–23.0); p = 0.001]. Significantly greater proportions
of patients receiving LDX than of those receiving ATX
responded to treatment at each study visit (all p \ 0.01)
(Fig. 3). By visit 9, 81.7 % (95 % CI 75.0–88.5) of patients
receiving LDX had responded compared with 63.6 %
(55.4–71.8) of those receiving ATX (p = 0.001).
The proportion of patients with a decrease of at least one
category from baseline in CGI-S score was significantly
greater in the LDX treatment group than in the ATX
treatment group by visit 4 [LDX, 92.3 % (95 % CI
87.5–97.1); ATX, 81.3 % (74.4–88.2); p \ 0.05] and by
visit 9 [LDX, 92.3 % (87.5–97.1); ATX, 79.7 %
(72.6–86.8); p \ 0.01].
There was no difference in mean (SD) ADHD-RS-IV
total score at baseline between treatment groups (Table 2).
Reductions from baseline in mean ADHD-RS-IV total
scores were observed in both treatment groups; by visit 9,
the mean (SD) ADHD-RS-IV total score was 16.3 (11.16)
in the LDX group and 22.5 (13.21) in the ATX group. The
mean (SD) change from baseline in ADHD-RS-IV total
score by visit 9 was -26.3 (11.94) in the LDX group and
-19.4 (12.82) in the ATX group. However, LDX treatment
was associated with significantly greater reductions from
baseline than ATX treatment (p \ 0.001 for each study
visit) (Fig. 4). By visit 9, the difference between LDX and
ATX in LS mean change (95 % CI) from baseline was
-6.5 (-9.3 to -3.6), with an effect size of 0.56. In addi-
tion, the differences (LDX minus ATX) in LS mean change
from baseline (95 % CI) by visit 9 were statistically sig-
nificant in favour of LDX (p \ 0.001) for both the inat-
tentiveness subscale [-3.4 (-4.9 to -1.8); effect size 0.53]
and the hyperactivity/impulsivity subscale [-3.2 (-4.6 to
-1.7); effect size 0.53].
3.4 Tolerability and Safety
TEAEs were reported by 92/128 patients (71.9 %) receiv-
ing LDX and 95/134 patients (70.9 %) receiving ATX
(Table 3). Most TEAEs were mild to moderate in severity
and no deaths or serious TEAEs were reported. The TEAEs
that led to discontinuation of LDX were agitation,
decreased weight, excoriation, indifference, irritability,
nausea, somnolence and tic. The TEAEs leading to dis-
continuation of ATX were headache, irritability, epigastric
discomfort, fatigue, influenza, malaise, nausea, sedation,
somnolence and upper abdominal pain.
At endpoint, both LDX and ATX were associated with
modest increases in mean systolic blood pressure, diastolic

















































































Fig. 3 Proportion of patients with a clinical response to LDX or ATX
treatment (defined as a CGI-I score of 1 or 2) at each weekly study
visit using LOCF. Values are shown as the proportion of responders
±95 % confidence intervals based on LOCF. ***p \ 0.001,
**p \ 0.01 based on a Cochran–Mantel–Haenszel test stratified by
country comparing LDX treatment with ATX. ATX atomoxetine,
CGI-I Clinical Global Impressions-Improvement, LDX lisdexamfeta-
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Fig. 4 Mean ADHD-RS-IV total scores (using LOCF) in patients
treated with LDX or ATX. Mean ADHD-RS-IV total scores are
shown ±95 % confidence intervals based on LOCF. ***p \ 0.001 for
LDX treatment compared with ATX based on an ANCOVA model of
the least-squares mean change from baseline including treatment
group (effect of interest), country (blocking factor) and the corre-
sponding baseline total score (covariate). ADHD attention-deficit/
hyperactivity disorder, ADHD-RS-IV ADHD Rating Scale IV,
ANCOVA analysis of covariance, ATX atomoxetine, LDX lisdexamfe-
tamine dimesylate, LOCF last-observation-carried-forward
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on treatment, 4/127 patients (3.1 %) receiving LDX, and
no patients receiving ATX, were classified as having a low
pulse rate (defined as B50 bpm), whereas 19/127 (15.0 %)
receiving LDX and 32/132 (24.2 %) receiving ATX met
the outlier criterion for high pulse rate (defined as
C100 bpm). Similar proportions of children (aged
6–12 years) experienced high systolic blood pressure
[defined as [120 mmHg; LDX, 12/94 (12.8 %); ATX,
11/98 (11.2 %)], or diastolic blood pressure [defined as
[80 mmHg; LDX, 11/94 (11.7 %); ATX, 13/98 (13.3 %)].
While no adolescent patients (aged 13–17 years) met the
predefined outlier criterion for high systolic ([140 mmHg)
or diastolic ([90 mmHg) blood pressure, supportive anal-
yses indicated that the proportions of adolescents with
systolic blood pressure [130 mmHg at any point during
treatment were 2/33 (6.1 %) for LDX and 3/34 (8.8 %) for
ATX; or for [120 mmHg were 20/33 (60.6 %) for LDX
and 16/34 (47.1 %) for ATX; and for diastolic blood
pressure[80 mmHg were 7/33 (21.2 %) for LDX and 6/34
(17.6 %) for ATX. No patients withdrew from the study as
a result of a clinically significant blood pressure or pulse
rate measurement.
The mean (SD) change in weight from baseline to
endpoint was greater for patients receiving LDX [-1.30 kg
(1.806)] than ATX [-0.15 kg (1.434)] (Table 4), and the
outlier criterion for weight reduction (defined as C7 %
reduction from baseline) was met by more patients
receiving LDX [34/127 (26.8 %)] than ATX [6/132
(4.5 %)]. At endpoint, shifts to lower BMI categories were
reported for 19/127 patients receiving LDX and 15/132 on
ATX, whereas 4/127 patients on LDX and 7/132 on ATX
had shifted to a higher BMI category. Five patients moved
into the underweight category (LDX, n = 4; ATX, n = 1);
all five were in the healthy weight (low) category at
baseline and all completed the study.
Table 3 Number and percentage of patients experiencing TEAEs
according to treatment group (safety population)




Any TEAE 92 (71.9) 95 (70.9)
Mild 51 (39.8) 54 (40.3)
Moderate 34 (26.6) 37 (27.6)
Severe 7 (5.5) 4 (3.0)
Any serious TEAEa 0 0
Any TEAE leading to discontinuation of
study drug
8 (6.3) 10 (7.5)
TEAEs reported by C5.0 % of patients in either treatment group
Decreased appetite 33 (25.8) 14 (10.4)
Decreased weight 28 (21.9) 9 (6.7)
Headache 17 (13.3) 22 (16.4)
Nausea 16 (12.5) 21 (15.7)
Insomnia 15 (11.7) 8 (6.0)
Fatigue 12 (9.4) 14 (10.4)
Nasopharyngitis 8 (6.3) 8 (6.0)
Constipation 8 (6.3) 2 (1.5)
Dry mouth 8 (6.3) 4 (3.0)
Irritability 8 (6.3) 3 (2.2)
Vomiting 6 (4.7) 13 (9.7)
Sedation 5 (3.9) 8 (6.0)
Somnolence 4 (3.1) 16 (11.9)
Upper abdominal pain 3 (2.3) 10 (7.5)
Abdominal pain 3 (2.3) 8 (6.0)
Upper respiratory tract infection 3 (2.3) 8 (6.0)
Diarrhoea 2 (1.6) 9 (6.7)
ATX atomoxetine, LDX lisdexamfetamine dimesylate, TEAE treat-
ment-emergent adverse event
a A serious TEAE is any untoward medical occurrence that results in
death; is life-threatening; requires inpatient hospitalization or pro-
longs existing hospitalization; results in persistent or significant dis-
ability/incapacity; is a congenital abnormality/birth defect; or is an
Important Medical Event. Important Medical Events may have been
considered as serious TEAEs when, based upon medical judgement,
they may jeopardize the patient and may require medical or surgical
intervention to prevent one of the outcomes listed above. The sponsor
required any new onset of seizures, syncope or loss of consciousness
to be reported as a serious TEAE
Table 4 Summary of vital signs, weight and ECG parameters (safety
population)
LDX (n = 128) ATX (n = 134)
Systolic blood pressure (mmHg)
Baseline, mean (SD) 107.9 (10.43) 106.2 (9.91)
Endpoint, mean change (SD) ?0.7 (9.08) ?0.6 (7.96)
Diastolic blood pressure (mmHg)
Baseline, mean (SD) 65.9 (8.32) 65.5 (7.98)
Endpoint, mean change (SD) ?0.1 (8.33) ?1.3 (8.24)
Pulse (bpm)
Baseline, mean (SD) 78.0 (10.11) 79.6 (9.18)
Endpoint, mean change (SD) ?3.6 (10.49) ?3.7 (10.75)
Weight (kg)
Baseline, mean (SD) 42.33 (16.618) 39.60 (14.639)
Endpoint, mean change (SD) -1.30 (1.806) -0.15 (1.434)
Heart rate (ECG assessment) (bpm)
Screening, mean (SD) 75.4 (11.72) 77.1 (10.24)
Visit 4, mean change (SD) ?3.5 (12.73) ?6.4 (10.08)
QTcF interval (ms)
Screening, mean (SD) 371.1 (17.72) 371.2 (17.00)
Visit 4, mean change (SD) -0.3 (14.74) ?1.9 (13.41)
Endpoint is the last on-treatment, post-baseline visit with a valid
assessment. The visit 4 ECG was added as a result of a protocol
amendment, and therefore an ECG was only obtained for some
patients at this visit (LDX, n = 76; ATX, n = 83)
ATX atomoxetine, bpm beats per minute, ECG electrocardiogram,
LDX lisdexamfetamine dimesylate, QTcF QT interval corrected using
Fridericia’s formula, SD standard deviation
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ECG parameters, assessed at screening and visit 4, are
shown in Table 4. In both treatment groups, some patients
experienced potentially clinically important (PCI) readings
for heart rate [defined as C100 bpm; LDX, 8/83 (9.6 %);
ATX, 8/91 (8.8 %)], PR interval [defined as C200 ms; LDX,
0; ATX, 1/91 (1.1 %)] and QTcF (QT interval corrected using
Fridericia’s formula) change from screening [defined as C30
or \60 ms; LDX, 2/83 (2.4 %); ATX, 1/90 (1.1 %)]. No
patients experienced a PCI QTcF absolute reading (defined as
C450 ms), and no patients withdrew from the study as a result
of a clinically significant ECG measurement.
4 Discussion
In this direct comparison between LDX and ATX, both
treatments led to improvements in symptoms and behav-
iours associated with ADHD in children and adolescents
who had previously experienced an inadequate response to
MPH therapy. However, the efficacy of LDX was signifi-
cantly faster to onset and greater than that of ATX. Both
therapies displayed safety profiles consistent with findings
from previous studies [9, 11–13, 28–30]. These results
support previous placebo-controlled trials of LDX, which
have demonstrated a robust treatment response in a range
of patient groups [9, 11–13].
In the current study, patients were required to have
experienced an inadequate response to previous MPH
therapy. In most cases, this was due to a lack of efficacy of
MPH (LDX, 75.6 %; ATX, 78.5 %). Despite this, the
majority of patients receiving LDX (81.7 %) and ATX
(63.6 %) were classified as treatment responders by visit 9,
according to CGI-I criteria. These results are of particular
relevance to the recent approval of LDX in Europe for the
treatment of children and adolescents whose response to
previous MPH treatment is considered clinically inade-
quate. The observation of a robust LDX treatment response
in patients previously treated with MPH is supported by a
post hoc analysis of a randomized, double-blind, US-based
study in 290 children with ADHD [31]. That study reported
no difference in response to LDX between the overall study
population and the subgroup of patients who were receiv-
ing MPH at study entry but were not considered well
controlled. In addition, several studies have demonstrated
that, although the overall response to MPH and amfetamine
is similar, the response to each varies among individual
patients, and non-response to one class of psychostimulant
does not predict non-response to a second [32].
A subgroup analysis of a double-blind, placebo-con-
trolled trial in 125 children with ADHD concluded that the
effects of ATX treatment were largely independent of
previous exposure to psychostimulants [33]. Based on
ADHD-RS-IV total scores, effect sizes relative to placebo
were 0.75 in pre-treated patients and 0.97 in patients who
had not received previous psychostimulant treatment
(interaction with treatment, p = 0.607) [33]. In support of
this conclusion, a meta-analysis including six randomized
controlled trials found that previous treatment with psy-
chostimulants did not influence clinical response to ATX
[34]. In contrast, one large (n = 516), double-blind, pla-
cebo-controlled, crossover study found that the proportions
of stimulant-naı¨ve children with ADHD who responded to
osmotic-release oral system MPH (OROS-MPH) and ATX
(64 and 57 %, respectively; effect sizes relative to placebo
based on ADHD-RS-IV total score, 1.0 and 0.9) were
higher than among those who had previously been treated with
a psychostimulant (51 and 37 %, respectively; effect sizes 0.8
and 0.5) [35]. It is unclear why there are discrepancies
between studies with respect to the impact of previous psy-
chostimulant treatment on ATX response, but potential dif-
ferences in the baseline severity of symptoms between
previously treated and treatment-naı¨ve patients may confound
outcomes [33]. Overall, these data support the importance of
alternative treatment options for patients who have not
improved satisfactorily on their current ADHD medication.
The observed shorter time to first clinical response
(CGI-I of 1 or 2) for LDX relative to ATX was not
unexpected as psychostimulants are generally recognized
to produce immediate treatment effects [3, 4]. In contrast,
estimates of the time required for ATX to reach its maxi-
mum effect generally range from 4 to 6 weeks [3, 4],
although, one study suggests that it may take as long as
12 weeks [36]. The mechanism that underlies this delay in
onset of action of ATX is not known. The dose-optimized
design of this study is likely to have had some influence on
the time to first clinical response in both treatment arms.
Importantly, however, as the dose-titration schedules for
both treatments followed current clinical guidelines, the
times to treatment response observed in this study are
relevant to clinical practice.
In addition to a faster onset of efficacy, the proportions
of patients who responded to treatment (CGI-I of 1 or 2) or
improved by at least one CGI-S category, and the
improvements in mean ADHD-RS-IV total and subscale
scores, all indicated that there was a greater reduction of
symptoms in patients receiving LDX than ATX by visit 9.
A meta-analysis of 32 clinical trials and a total of 15
ADHD medications supports these observations, conclud-
ing that both short- and long-acting psychostimulants were
significantly more effective than non-stimulants [37]. It
should be noted, however, that ATX, dosed once daily in
the present study, may require twice-daily dosing to
achieve its maximum beneficial effect [38].
A similar proportion of patients in both treatment groups
reported TEAEs; most TEAEs were mild or moderate in
severity. The proportions of patients who withdrew from
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the study as a result of a TEAE were also similar. The most
frequently reported TEAEs in the LDX treatment group
(decreased appetite, decreased weight, headache, nausea
and insomnia) and in patients receiving ATX (headache,
nausea, somnolence, decreased appetite and fatigue) are
consistent with findings from previous studies [9, 11–13,
28–30]. There was a greater decrease in mean weight in
patients receiving LDX than ATX, and more patients
receiving LDX than ATX met the outlier criterion for weight
loss (C7 % reduction from baseline). In addition, more
patients receiving LDX (n = 4) than ATX (n = 1) moved
into the underweight BMI category, all of whom were in the
healthy weight (low) category at baseline. These results are
consistent with previously reported evidence that psycho-
stimulants are associated with loss of appetite and weight
loss. One systematic review reported that children treated
with psychostimulants showed a height deficit of approxi-
mately 1 cm/year during the first 1–3 years of treatment [39]
and clinical guidelines recommend that patients receiving
ADHD medication are monitored for weight, height, BMI
and appetite every 6 months [40, 41]. High calorific snacks,
late evening meals, dosing after meals, drug holidays, or
switching to a different class or formulation of medication
may be beneficial in some patients [41].
The mean increases in blood pressure and pulse rate
observed in both treatment arms in this study were rela-
tively modest. It is recognized, however, that some patients
receiving ADHD medications may experience blood pres-
sure and pulse rate above the 95th percentile, and clinical
guidelines recommend that patients are assessed for heart
disease or symptoms suggesting significant cardiovascular
disease, and family history of sudden unexpected death
before commencing treatment [40, 41]. Once on medica-
tion, patients’ blood pressure and heart rate should be
monitored at least every 6 months and, if measurements are
above the 95th percentile, it is recommended that patients
have a dose-reduction or drug holiday, or are referred to a
cardiologist [41]. In the present study, a higher proportion
of patients receiving ATX than LDX met the outlier cri-
terion for high pulse rate. With the exception of weight and
pulse rate, changes in mean vital sign and ECG parameters,
and in the frequency of outliers and PCI observations, were
similar between treatment groups.
The strengths of this study include its head-to-head,
randomized, double-blind, parallel-group, dose-optimized
design, and the large number of patients enrolled from
multiple countries. These results are particularly relevant to
the recent approval of LDX in Europe for the treatment of
children and adolescents whose previous MPH treatment is
considered clinically inadequate. However, it is unclear
whether this patient population, who met detailed inclu-
sion/exclusion criteria specifically related to prior MPH
response, would have favoured a response in one treatment
arm over the other. Also, as noted earlier, certain elements
of the study design (the 9-week duration and once-daily
dosing regimen) may not have elicited the maximum
potential treatment benefit of ATX [36, 38].
5 Conclusions
A clinically relevant difference in efficacy was observed
between LDX and ATX, with LDX associated with a sig-
nificantly faster, and more robust, treatment response in
children and adolescents with ADHD of at least moderate
severity and a previous inadequate response to MPH therapy.
Both treatments displayed safety profiles consistent with
findings from previous clinical trials. These findings will aid
clinicians when developing treatment plans for patients who
have achieved unsatisfactory improvements on MPH therapy.
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